FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Virginia American Water Celebrates Earth Day with Environmental Initiatives & Water Saving Tips
Supreme Court Might Decide Future of Kalshi Sport Event Contracts
Shield AI In Running For US Navy's $800 Million Surveillance Program
Clearmind Medicine (CMND) Stock: Positive Trial Data Boosts Outlook for CMND-100 Therapy
Trump Claims Military Success in Ongoing Conflict
U.S. Market Sees Significant Growth Amid Positive Earnings Forecasts
argenx Presents New Efficacy Data for VYVGART at Neurology Meeting
Ramit Sethi Critiques Bill Ackman Over Tax Proposal Response
Mastercard Outpaces PayPal in Digital Payments Growth Potential
Ameriprise Expected to Exceed Earnings Estimates in Upcoming Report
CN (CNI) Poised for Potential Earnings Surprise in Upcoming Report
CME Group Anticipates Revenue and Earnings Growth for First Quarter 2026
Morgan Stanley Identifies Top Stock Picks Amid Market Uncertainty
Oracle Outpaces ServiceNow in Cloud Growth and AI Initiatives
Procter & Gamble and Charmin Announce Tree Planting Initiative
TSMC Receives Upgrade to Buy Amid Positive Earnings Outlook
Wells Fargo CEO Highlights Strong Economy Amid Consumer Concerns
Iran Plans Negotiation Talks in Pakistan Amid Uncertainty
Pakistan Optimistic About Iran's Participation in Upcoming Talks
LAGARDE SAYS LIMITED SIGNS OF SUPPLY CHAIN DISRUPTIONS SO FAR...
US Stocks Decline as Doubt Casted on US-Iran Ceasefire Extension
Enterprise AI Goes Vertical and Investors Follow Fast
US Export-Import Bank boosts energy lending during Iran conflict
LAGARDE SAYS EURO ZONE NOT YET IN ADVERSE SCENARIO...
Bad Bunny evitó pérdidas en conciertos de Medellín con seguro personalizado contra el mal clima
Spirit Floats US Government Stake to Avoid Potential Liquidation
Southern Company increases dividend for 25th consecutive year
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings
ECB LAGARDE: NO EASY PATH BACK TO PRE-WAR SITUATION...
Elon Musk Ignores French Prosecutors, Widening Tech Rift With Europe
AtkinsRéalis Confirms CANDU® Monark Reactor Power Rating
William Hill’s owner can squeeze extra winnings from its suitor
Kevin Warsh to say Fed independence not threatened by political pressure
ECB LAGARDE: WAR'S STOP-START NATURE MAKES IMPACT ,TO GAUGE...
Bank of America Raises Price Target for Seagate Technology Ahead of Earnings Report
Enbridge Reports 31 Years of Dividend Growth Amid Strong Financial Backing
Analysts Adjust Price Targets for Halliburton Amid Iran Conflict
ServiceNow Set to Report Q1 Earnings with Expected Revenue Growth
Quanta Services Poised for Strong Earnings Performance
Vertiv Scheduled to Release Q1 Earnings on April 22
American Airlines Anticipates Strong Q1 Earnings Amid Cost Challenges
Traffic Through Strait of Hormuz Declines Sharply Following Conflicting Claims
Iran to Dispatch Negotiating Team to Pakistan
Fate of Iran peace talks uncertain as deadline approaches for end of ceasefire
Caesars extends discussion period on potential Fertitta takeover, Bloomberg News reports
US Supreme Court seems ready to back SEC in fight over ’disgorgement’ power
Fed chief nominee Warsh commits to central bank’s independence, with limits
Analyst Names Alphabet Top Pick Ahead Of Cloud Next 2026
ECB LAGARDE: ECONOMIC PICTURE REMAINS DEEPLY UNCERTAIN...
Nektar Therapeutics Shares Surge Following Positive Alopecia Trial Results
Nektar Therapeutics experienced a significant increase in its stock price on Monday after announcing favorable results from a late-stage trial for its alopecia areata treatment. The trial, which lasted one year, involved a Phase 2b study where nearly 40% of participants receiving the drug rezpegaldesleukin demonstrated a 50% or greater improvement in their alopecia severity scores.
In comparison, only 13.6% of patients who received a placebo showed similar improvements. The trial's findings indicate a promising potential for rezpegaldesleukin as a treatment option for this chronic autoimmune condition that leads to hair loss.
The most frequently reported side effects were mild-to-moderate injection site reactions, which were generally resolved within five days. Nektar's positive trial results mark a significant step forward in the search for effective treatments for alopecia areata.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News